Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

12.42 +0.43 (+3.59%)
Streaming Delayed Price Updated: 10:05 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Biotech Arvinas Stock Earns 82 RS Rating ↗
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
News headline image
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Analyst Ratings For Arvinas ↗
 
Via Benzinga
News headline image
Navigating 7 Analyst Ratings For Arvinas ↗
 
Via Benzinga
News headline image
Arvinas: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
From Arvinas Inc.
Via GlobeNewswire
News headline image
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains ↗
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist. 
Via Talk Markets
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
From Arvinas Inc.
Via GlobeNewswire
News headline image
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
News headline image
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
News headline image
ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024 ↗
ARVN stock results show that Arvinas beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
News headline image
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - 
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
News headline image
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
News headline image
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Chief Financial Officer Transition
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.